Myelodysplastic syndromes: It is all in the genes

Journal of Clinical Oncology

Volumn 30, Issue 8, 2012, Pages 774-776

  Sekeres, Mikkael A ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; LENALIDOMIDE;

CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER EPIDEMIOLOGY; CYTOGENETICS; EDITORIAL; GENE MUTATION; HUMAN; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; TUMOR GENE;

FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MYELODYSPLASTIC SYNDROMES;

EID: 84858850533     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.39.7869     Document Type: Editorial

References (28)

1. Greenberg P, Cox C, LeBeau MM, et al: International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079-2088, 1997 (Pubitemid 27132124)
2. Kantarjian H, Issa JP, Rosenfeld CS, et al: Decitabine improves patient outcomes in myelodysplastic syndromes: Results of a phase III randomized study. Cancer 106:1794-1803, 2006
3. List A, Dewald G, Bennett J, et al: Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 355:1456-1465, 2006 (Pubitemid 44511560)
4. Silverman LR, Demakos EP, Peterson BL, et al: Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the Cancer and Leukemia Group B. J Clin Oncol 20:2429-2440, 2002 (Pubitemid 34525728)
5. US Cancer Statistics Working Group: United States Cancer Statistics: 1999-2007 Incidence and Mortality Web-Based Report, in U.S. Department of Health and Human Services Centers for Diesease Control and Prevention, National Cancer Institute. Atlanta, GA, Centers for Disease Control and Prevention, 2010
6. Cogle CR, Craig BM, Rollison DE, et al: Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: High number of uncaptured cases by cancer registries. Blood 117:7121-7125, 2011
7. Aul C, Gattermann N, Schneider W: Age-related incidence and other epidemiological aspects of myelodysplastic syndromes. Br J Haematol 82:358-367, 1992
8. Smith MR, Neuberg D, Flinn IW, et al: Incidence of therapy-related myeloid neoplasia after initial therapy for chronic lymphocytic leukemia with fludarabinecyclophosphamide versus fludarabine: Long-term follow-up of US Intergroup Study E2997. Blood 118:3525-3527, 2011
9. Sekeres MA: Epidemiology, natural history, and practice patterns of patients with myelodysplastic syndromes in 2010. J Natl Compr Canc Netw 9:57-63, 2011
10. Sekeres MA, Schoonen WM, Kantarjian H, et al: Characteristics of US patients with myelodysplastic syndromes: Results of six cross-sectional physician surveys. J Natl Cancer Inst 100:1542-1551, 2008
11. Flach J, Dicker F, Schnittger S, et al: An accumulation of cytogenetic and molecular genetic events characterizes the progression from MDS to secondary AML: An analysis of 38 paired samples analyzed by cytogenetics, molecular mutation analysis and SNP microarray profiling. Leukemia 25:713-718, 2010
12. Jiang Y, Dunbar A, Gondek LP, et al: Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood 113:1315-1325, 2009
13. Van den Berghe H, Cassiman JJ, David G, et al: Distinct haematological disorder with deletion of long arm of no. 5 chromosome. Nature 251:437-438, 1974
14. List A, Kurtin S, Roe DJ, et al: Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 352:549-557, 2005 (Pubitemid 40204668)
15. Visconte V, Makishima H, Jankowska A, et al: SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts. Leukemia [epub ahead of print on September 2, 2011]
16. Jankowska AM, Makishima H, Tiu RV, et al: Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. Blood 118:3932-3941, 2011
17. Jädersten M, Saft L, Smith A, et al: TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. J Clin Oncol 29:1971-1979, 2011
18. Bejar R, Stevenson K, Abdel-Wahab O, et al: Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 364:2496-2506, 2011
19. Thol F, Friesen I, Damm F, et al: Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes. J Clin Oncol 29:2499-2506, 2011
20. Ko M, Huang Y, Jankowska AM, et al: Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 468:839-843, 2010
21. Schanz J, Tüchler H, Solé F, et al: New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol 30:820-829, 2012
22. Tiu RV, Gondek LP, O'Keefe CL, et al: Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies. Blood 117:4552-4560, 2011
23. Garcia-Manero G, Yang H, Bueso-Ramos C, et al: Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 111:1060-1066, 2008 (Pubitemid 351213383)
24. Sekeres MA, List AF, Cuthbertson D, et al: Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes. J Clin Oncol 28:2253-2258, 2010
25. Garcia-Manero G, Estey EH, Jabbour E, et al: Final report of a phase II study of 5-azacitidine and vorinostat in patients (pts) with newly diagnosed myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) not eligible for clinical trials because poor performance or presence of other comorbidities. Presented at the 53rd ASH Annual Meeting & Exposition, San Diego, CA, December 10-13, 2011 (abstr 608)
26. Greenberg P, Tuechler H, Schanz J, et al: Revised International Prognostic Scoring System (IPSS-R), developed by the International Prognostic Working Group for Prognosis in MDS (IWG-PM). Leuk Res 35:S6, 2011
27. Kantarjian H, O'Brien S, Ravandi F, et al: Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer 113:1351-1361, 2008
28. Komrokji RS, Corrales-Yepez M, Ali NA, et al: Validation of the MD Anderson Prognostic Risk Model for patients with myelodysplastic syndrome. Cancer [epub ahead of print on September 28, 2011]